Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”

Detalles Bibliográficos
Autores principales: Putzke, Joerg, Haughie, Scott, Zou, Kelly H., Ranganna, Gopinath M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084790/
https://www.ncbi.nlm.nih.gov/pubmed/33860919
http://dx.doi.org/10.1007/s40259-021-00476-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084790/
https://www.ncbi.nlm.nih.gov/pubmed/33860919
http://dx.doi.org/10.1007/s40259-021-00476-9

Ejemplares similares